26 January 2023 - - US-based biomagnetic cardiac imaging solutions Genetesis, Inc has appointed three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its flagship solution, CardioFlux, the company said.

This announcement comes in anticipation of market authorization from the FDA, which Genetesis expects to see later this year.

Dr. Robert Takla joins as Chief Medical officer, where he will develop and lead clinical strategy while building out innovative partnerships with other key players within heart medicine.

Most recently, Dr. Takla served as the chair and medical director of Emergency Medicine at Ascension St. John Hospital in Detroit, Michigan.

Prior to joining a leadership team at Genetesis, Dr. Takla was an early proponent of the use of magnetocardiography in the emergency department and led several early trials researching the efficacy of MCG in the efficient diagnosis of acute heart disease.

Dr. Mazen Albaghdadi joins as vice president of Medical Affairs, where he will oversee the intersection of research and clinical science with the company's commercial activity.

Albaghdadi currently practices interventional cardiology in his positions as the director of Cardiac Catheterization Laboratory and Associate Program director of Cardiology Fellowship at Naples Heart Institute in Naples, Florida.

With over 50 publications to his name, Dr. Albaghdadi is a champion of early-stage medical devices with novel applications in cardiac science.

Kevin Hillsman joins as vice president of Market Access, where he will oversee the expansion of patient access to CardioFlux by establishing new reimbursement pathways and executing other key market access initiatives.

Hillsman's recent experiences include a successful stint within HeartFlow's Market Access team followed by time spent leading Market Access at Abbott Labs for their Cardiometabolic division.

In these roles, Hillsman demonstrated an ability to navigate the complex payor ecosystem surrounding both Medicare and commercial health plans, bridging the gap between health plans and medical device providers to increase patient access to innovative and impactful solutions supporting cardiac health.

Genetesis, Inc. is a medical imaging company redefining the way ischemic heart disease is detected and understood.